RxDoctor Payments Data

Farzaneh Moin

Optometrist · Irvine, CANPI 1144602426

Payments from drug & device makers

$5,515in general payments, 2019–2025

Across 138 payments — averaging $39.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch & Lomb Americas Inc.$759
  • Sun Pharmaceutical Industries Inc.$726
  • Alcon$695
  • Coopervision Inc.$631
  • AbbVie$503
  • Oyster Point Pharma, Inc.$460
  • plus $2K from 13 others

What the payments were for

  • Travel & lodging$2795%
  • Food & beverage$5,04391%
  • Entertainment$1944%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,515 in reported general payments places this provider in the 90th percentile of 6,778 optometrist providers in California.

See all optometrist providers in California

Medicare billing

Part B allowed, 2024
$17,955
Medicare patients
97
Services billed
151

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XiidraLifitegrast160$186,157
RestasisCyclosporine37$41,422
MieboPerfluorohexyloctane/Pf32$26,136
Cyclosporine39$23,269
CequaCyclosporine24$18,374
TyrvayaVarenicline Tartrate17$12,428
VyzultaLatanoprostene Bunod19$8,482
LumiganBimatoprost11$5,376
ZerviateCetirizine Hcl12$2,725
Prednisolone Acetate65$1,620
Latanoprost116$1,061
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha78$757
Ofloxacin58$543
Timolol Maleate35$344
Cromolyn Sodium12$132

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb Americas Inc.Xiidra, Miebo, Vyzulta$759$220,775211 claims
AbbVieRestasis, Lumigan$503$46,79848 claims
Sun Pharmaceutical Industries Inc.Cequa$726$18,37424 claims
Oyster Point Pharma, Inc.Tyrvaya$460$12,42817 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,778 optometrist providers in California.

Other optometrist in Irvine

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →